- Alkermes' narcolepsy Phase 3 success; Boehringer's antibody dealPlus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcoleps…Endpoints · 2mo ago↗ source
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 2mo ago↗ source
- Knit Health raises $11.6M for 'fundamentally different' approach to healthcare AIA startup that spun out of UC Berkeley aims to improve healthcare operations by getting AI to think like a doctor would. Knit Health launched with $11.6 million in seed funding co-led by Uncork Cap…